A structured assessment process can determine compliance to lifecycle process-validation requirements for biopharmaceuticals.
Ajay Pazhayattil
Advertisement
Articles by Ajay Pazhayattil
483s and Warning Letters Point to Inadequate Quality Oversight
FDA’s focus on the quality culture and its request for quality metrics may ensure a successful company-CMO relationship.
Advertisement
Latest Updated Articles
Quality Metrics and CMO AgreementPublished: May 15th 2017 | Updated:
- Solving Pharma’s Quality Unit Identity Crisis
Published: July 1st 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
5
